Cancer biomarker discovery is the process of identifying measurable biological indicators associated with the presence, progression, or treatment response of cancer. Biomarkers may take the form of altered genes, proteins, metabolites, microRNAs, or other molecular signatures detectable in tissue, blood, stool, or o…
Cancer biomarker discovery is the process of identifying measurable biological indicators associated with the presence, progression, or treatment response of cancer. Biomarkers may take the form of altered genes, proteins, metabolites, microRNAs, or other molecular signatures detectable in tissue, blood, stool, or other samples, and they support early diagnosis, prognosis, patient stratification, and monitoring of therapeutic efficacy. The discovery process typically combines high-throughput molecular profiling, validation across patient cohorts, and assessment of analytical and clinical performance to ensure that a candidate marker is reliable and clinically meaningful. Advances in genomics, proteomics, and microfluidics have expanded the ability to detect biomarkers with greater sensitivity and at lower cost, including non-invasive approaches suited to screening. Research relevant to this field in the collection includes work using microfluidic assays and microRNAs for the diagnostic screening of colon cancer in stool and the quantification of microRNAs by digital PCR for colon-cancer diagnosis. These peer-reviewed, open-access studies illustrate how the search for robust molecular markers is advancing tools for cancer detection and management, situating cancer biomarker discovery within ongoing research in Cancer Genetics And Biomarkers.
8 peer-reviewed articles, ranked by relevance. Each links to its DOI.
The 8 articles above have been cited 29 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
A sample of recent works citing this journal's research on Cancer Biomarker Discovery, linking to each citing work.